SGCB and interstitial lung disease: In addition, consistent with prior reports, the poor pulmonary selectivity of the three sGC stimulators showed in our study was comparable with results observed in several animal models [26,27] and in patients with PAH, distal chronic thromboembolic PH or PH associated with mild to moderate interstitial lung disease [28] and in patients with PH associated with COPD [29] where this family of compounds did not demonstrated pulmonary selectivity.